Shares of Rubicon Research soared to a record, surging over 11% after reporting a 52% rise in revenue and nearly doubling profit in the June quarter, amid investor optimism over margin stability and capacity expansion.
Rubicon Research shares surged to a record on Monday after the drugmaker posted a sharp jump in June-quarter earnings and raised its margin outlook for the year. The stock hit Rs 1,808 during the session and finished at Rs 1,798.70, up 11.09%, as investors rushed in after the results showed broad-based growth across revenue, profit and operating performance.
The company reported revenue of Rs 534 crore for the first quarter of fiscal 2027, up 51.6% from a year earlier, while profit after tax climbed 95.8% to Rs 84.8 crore. EBITDA rose 64.6% to Rs 131 crore. Rubicon said margins improved even though gross margin eased slightly because it used more outsourced manufacturing during the quarter, and management now expects operating EBITDA margins to stay at 23% or above for the full year.
Momentum in the stock has been striking. According to the company’s latest trading data cited by EquityPandit and LiveMint, more than 3 million shares changed hands across the NSE and BSE, far above normal volume. The shares have risen more than 160% so far this year, lifting them well past the previous high of Rs 1,686.45 set only four days earlier.
Investor confidence has also been helped by progress at Rubicon’s Pithampur site, which the company bought last year. After a USFDA inspection in late June, the facility received just two procedural observations under Form 483, and the company is still awaiting the final report. Rubicon expects commercial ramp-up at the site in early 2027, a timeline that investors appear to read as evidence that it can bring new capacity onstream without major setbacks. Stock analysis sites also show the company’s strong recent valuation gains, with the shares trading well above levels seen in late July.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
